Clinical and Genetic Aspects of Refractory Forms of Multiple Myeloma Development


Н. І. Костюкова
З. І. Россоха
Н. Г. Горовенко
С. В. Видиборець


Treatment of multiple myeloma has progressed significantly over the past years after the introduction of immunomodulation drugs and proteasome inhibitors. The median of patients survival has improved. All patients with multiple myeloma have relapses during a different time interval. The duration of the achieved remission in patients with a relapse of multiple myeloma becomes shorter with each subsequent case. The choice of regimen for relapse of multiple myeloma is very complex. It depends on a number of factors, including the previous induction regimen, the number of lines of the previous therapy, and the degree of aggression of relapse. The article is devoted to peculiarities of drug resistance formation in the first line therapy in patients with multiple myeloma by assessing of genetic markers (deletion variants of GSTT1, GSTM1 genes, GSTP1 (А313G), MDR1 (C3435T)) and clinical-hematological, laboratory characteristics.

The objective: to determine the peculiarities of drug resistance establishement in patients with multiple myeloma by assessing of genetic markers (deletion variants of GSTT1, GSTM1 genes, GSTP1 (А313G), MDR1 (C3435T)) and clinical signes (hematological, laboratory characteristics) for predicting the effectiveness of treatment.

Materials and methods. We conducted analysis of 68 clinically-laboratory indexes of 130 patients with multiple myeloma and their results of molecular-genetic research of deletion polymorphism of genes GSTT1, GSTM1, polymorphism А313G, C3435T genes GSTP1, MDR1.

Results. It was determined that important predictors of development of refractory forms of multiple myeloma is allelic polymorphism of gene GSTM1 of patients, higher level α2-globulin and calcium in blood serum till the beginning of disease.

Conclusions. Implementation of predicative model taking into account polymorphism GSTM1, of level α2-globulin and calcium in blood serum till the beginning of treatment raises efficiency of evaluation of individual prognosis of response on treatment.


How to Cite
Костюкова, Н. І., Россоха, З. І., Горовенко, Н. Г., & Видиборець, С. В. (2019). Clinical and Genetic Aspects of Refractory Forms of Multiple Myeloma Development. Family Medicine, (2), 54–58.
For practicing physicians


Gorovenko N., Kostyukova N., Vydyborets S., Kyryachenko S., Gorenko L., Mazurik M., Popova O., Rossokha Z. The association of MDR1 gene C3435T polymorphism with CMV reactivation in patients with multiple mieloma. 27th International Congress of Chemotherapy (ESMID): Milan, Italy, 2011, abstract, p.1908.

Iskrov I., Lendina I., Suvorov D., Gerasimovich O. Terapija rezidivov I resistentnych form mnozhestvennoj mielomy: klinicheskij opyt [Treatment of relapses and resistant forms of multiple myeloma: case report]. Hematology. Transfusiology. Eastern Europe, 2018, vol. 4, no.3, pp. 411–418.

Multiple myeloma: ESMO Clinical practice Gudelines for diagnosis, treatment and follow-up. Leukaemia&Myeloma 2018. ESMO Pocet Gudelines. European Society by Medical Oncology, 123 p.

Rossokha Z., Kostyukova N., Kiryachenko S., Vydyborets S., Gorovenko N. The predictive model of chemotherapy response in multiple myeloma patients. Experimental oncology. 2013, vol. 35, no.2, p. 145.

Andreeva N.E., Iliashenko E.Yu., Saridi E.Yu. Retrospective analysis of cytostatic therapy of patients with multiple myeloma. Problems of hematology and blood transfusion, 2002, vol. 3, pp. 7–11.

Votiakova O.М. Modern therapy of multiple myeloma. Fundamental and applied researches in oncohematology. Bulletin of Siberian medicine. Supplement 3. 2008, pp. 33–41.

Kriachok І.А. Clinically-laboratory markers of prognosis of disease progression and response on combined treatment including high-dosage chemotherapy and transplantation of stem cells of patients with multiple myeloma. Ukrainian Medical Journal, 2005, no.4, pp. 132–138.

Кriachok І.А. Modern standards of diagnosis and treatment of patients with multiple myeloma. Ukrainian Medical Journal. 2010, no. 2, pp. 91–97.

Мanziuk L.V. Anti RANKL homogeneous antybody and its usage in oncology. Practical oncology. 2011, vol. 12, no. 3, pp. 132–135.

Novosad О.І., Kriachok І.А., Kadnikova Т.V., Тytorenko І.B., Sychova Т.V., Кostiukova N.І. Experience of implementation of thalidomide in treatment multiple myeloma. Likars’ka sprava, 2010, no. 3-4 (1105), pp. 79–86.

Buda G., Maggini V., Galimberti S. at el. MDR1 polymorphism Influences the outcome of multiple myeloma. B. J. Haematol. 2007, no 2, pp. 454–456.

Dumontet C., Landi S., Reimen T. at el. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplantation. 2010, vol. 45, pp. 1316–1324.

Lonial Sagar. Relapsed Multiple Myeloma. American Society of Hematology. 2010, pp. 303–310.

Richardson P., Mitsiades C., Schlossman R., Ghobrial I., Hideshima T., Chauhan D., Munshi N., Anderson K. Treatment of Relapsed and Refractory Multiple Myeloma. American Society of Hematology. 2007, pp. 317–323.